PMID: 8105705Nov 1, 1993Paper

Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia

The American Journal of Psychiatry
H Y MeltzerB Snitz

Abstract

The goal of this study was to determine whether clozapine is a cost-effective treatment for treatment-resistant schizophrenia. Data were collected on 96 treatment-resistant patients with schizophrenia for 2 years before they entered a clozapine treatment study and for at least 2 years after they entered the study. Information about the cost of inpatient and outpatient treatment, housing costs, other costs, and family burden through direct interview or questionnaire of these patients and their families were available for 47 of the 96 patients. Data on lost income and Social Security disability insurance were also obtained. Outcome measures included psychopathology, quality of life, global functioning, work function, and rehospitalization. The cost of treatment was significantly decreased in the patients who continued clozapine treatment for at least 2 years. This was primarily due to a dramatic decrease in the frequency and cost of rehospitalization. Costs were nonsignificantly lower in patients who dropped out of treatment. The estimated total 2-year cost for the 59 patients who continued clozapine treatment, the 34 patients who dropped out, and the three who interrupted treatment decreased from $7,390,206 to $5,719,463, a savi...Continue Reading

Citations

Jan 28, 1998·Clinical Therapeutics·C Langley-Hawthorne
Jan 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·W M Glazer
Jan 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·G BondolfiH Dufour
May 1, 1997·Journal of Clinical Pharmacology·P F Buckley
Nov 1, 1995·The Journal of Emergency Medicine·M J Tueth
Jun 17, 1998·Biological Psychiatry·J LaurielloA Pfefferbaum
Feb 1, 1995·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·R A BerzonH H Tilson
Jan 1, 1999·International Journal of Psychiatry in Clinical Practice·D Taylor, K Aitchison
Jan 1, 1997·Current Medical Research and Opinion·H Y Meltzer
May 4, 2004·Current Medical Research and Opinion·Stephen Layton, Martin Barbeau
Sep 1, 1994·Psychosomatics· Feldman
Jan 27, 1999·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·D V JesteJ Lacro
Sep 6, 2013·Acta Psychiatrica Scandinavica·S GeeD Taylor
Aug 30, 2005·International Journal of Law and Psychiatry·Robert Rosenheck
Apr 29, 1998·The Psychiatric Clinics of North America·J M Zito
Jan 1, 1998·European Psychiatry : the Journal of the Association of European Psychiatrists·W RösslerI Reinhard
Feb 19, 1999·Epidemiologia e psichiatria sociale·M Percudani, M Knapp
Mar 20, 1999·The Annals of Pharmacotherapy·C S BrownN G Parker
Jan 1, 1998·International Journal of Psychiatry in Clinical Practice·B D ByromA T Kilpatrick
Nov 7, 2000·PharmacoEconomics·E Lindström, K Bingefors
Jul 4, 2002·Journal of Psychopharmacology·K P HayhurstS W Lewis
Jul 19, 2008·Journal of Psychopharmacology·A WheelerG Robinson
Oct 8, 1998·The Annals of Pharmacotherapy·P F Buckley
Jul 10, 2018·Current Opinion in Psychiatry·Kevin J LiLynn E DeLisi
Aug 1, 1997·Journal of Clinical Psychopharmacology·G Chouinard, P S Albright
Sep 15, 2005·Journal of Clinical Psychopharmacology·Roy H PerlisPhilip S Wang
Jun 5, 2003·The British Journal of Psychiatry : the Journal of Mental Science·Andy DugganRobert Kerwin
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·M Knapp
Aug 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·K J Aitchison, R W Kerwin
Jan 1, 1995·European Psychiatry : the Journal of the Association of European Psychiatrists·H Meltzer
Jan 1, 1998·European Psychiatry : the Journal of the Association of European Psychiatrists·W RösslerI Reinhard
Aug 22, 2001·European Psychiatry : the Journal of the Association of European Psychiatrists·J LynchJ S Hellewell
Jan 5, 2002·The Journal of Nervous and Mental Disease·M J SernyakG Ripper
Feb 10, 1999·The Journal of Nervous and Mental Disease·T E SmithJ F Clarkin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
Deanna L KellyR R Conley
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
R A DicksonS J Warden
© 2021 Meta ULC. All rights reserved